Krish Patel
@KrishPatelMD
Followers
939
Following
1K
Media
39
Statuses
375
Director #lymphoma #Research @SarahCannonDocs @SCRIOncology #Duke alum x4. Foodie. Dad of 2. Husband. Tweets my own, not medical advice. #cll #lymsm
Nashville, TN
Joined November 2013
We’re celebrating Dr. Howard “Skip” Burris’s remarkable career as he prepares to retire as President & CMO of SCRI. His legacy: 850+ first-in-human trials, countless lives impacted. 💙 Welcome new leaders and read the full update: https://t.co/rmTeT1P8ug
1
1
13
What's New in #DLBCL care? Learn how BTK inhibitors, antibody-based therapies, and bispecifics are changing the game for frontline & relapsed/refractory disease. Join this expert-led #MedEd program featuring Krish Patel, MD (@KrishPatelMD). #PeerView 🔗
lrn.peerview.com
See a new #DLBCL activity via @PeerView #MedEd @KrishPatelMD
0
3
5
Fabulous talk on challenges and opportunities in trials for Cell Tx in GI Malignancies from @MeredithPelster @SarahCannonDocs #CellTx #GIOnc #SeattleCT25
1
2
19
This Friday and Saturday in Seattle! Take a look at the agenda and the list of speakers! https://t.co/qsMx6gZLMk Looking forward to seeing you all! @binaytara @fredhutch #SeattleCT25
3 DAYS TO GO! Join @mshadman and @KrishPatelMD at #SeattleCT25! Connect with leading oncologists from @fredhutch @uwmedicine @SarahCannonDocs @NebraskaMed @MDAndersonNews @ProvSwedish. Register TODAY: https://t.co/B7nAlcElat
#MedX #MedTwitter #leusm #lymsm #CLLsm #hemepath #ALL
0
6
29
3 DAYS TO GO! Join @mshadman and @KrishPatelMD at #SeattleCT25! Connect with leading oncologists from @fredhutch @uwmedicine @SarahCannonDocs @NebraskaMed @MDAndersonNews @ProvSwedish. Register TODAY: https://t.co/B7nAlcElat
#MedX #MedTwitter #leusm #lymsm #CLLsm #hemepath #ALL
1
7
15
Excited to share a story about the power of clinical trials! Please see our article on oncogene examining a robust and durable response with iNKT cell therapy in a patient with very refractory germ cell tumor. @SarahCannonDocs and @SCRIOncology
https://t.co/zkR8pOI3SU
nature.com
Oncogene - Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumor
1
2
17
Can off-the-shelf iPSC-derived NK cells change the game for B-cell lymphoma? @tix_tobi and I had the opportunity to reflect on an early-phase study by Strati et al, published in @TheLancetHaem , studying FT516—a non-CAR-bearing, iPSC-derived NK-cell Tx. https://t.co/6u1mUFgWtV
1
5
12
CONGRESS | #18ICML | PRESENTATION Krish Patel @KrishPatelMD, Sarah Cannon Research Institute, presents global phase Ib results of JNJ-90014496, a CD19/CD20 bispecific CAR T-cell therapy, in R/R LBCL (N = 48). At the RP2D (75M cells), ORR and CRR were 95% and 80%, respectively,
0
4
5
Join the CME/ACPE-accredited 2025 Seattle Cellular Therapy Summit, where leading experts deliver insights on CAR T therapies, lymphoma management, and breakthrough strategies for hematologic malignancies. Register NOW:
0
1
2
🎥 Hear from Dr. @KrishPatelMD as he shares what to expect at PeerView’s TownHall symposium on #CLL care during #ASCO25! Join him, @NitinJainMD, @MCThompsonMD & @CllSociety for this interactive session on 5/31. 📍 Grand Ballroom B, Hyatt Chicago 🔗 https://t.co/QLXv6YLvWw
0
13
19
Navigating new options in #CLL care? Join us and @PeerView at #ASCO25 for an interactive TownHall featuring expert insights on BTK inhibitors, CAR-T, and personalized strategies! Learn more at https://t.co/5dsKO8yRIf
@NitinJainMD @KrishPatelMD @MCThompsonMD
0
18
24
Save the date for our next Seattle Cellular Therapy Summit. Outstanding line of speakers and great topics. @KrishPatelMD @binaytara @fredhutch
#SeattleCT25
https://t.co/3kQkcdimuc$
1
6
23
CLL Community Conversations on Modern Care: Participate in a dynamic #PeerView TownHall and engage in meaningful dialogue on real-world challenges in #CLL care. 5/31 at 6:30 PM CDT. Produced w/ @CLLSociety. https://t.co/QLXv6YLvWw
#ASCO25 @NitinJainMD @MCThompsonMD @KrishPatelMD
0
7
10
We're thrilled to bring you some fantastic content from #iwCART25!💉🩸 In an exclusive discussion, @KrishPatelMD, @DanilovLab, and @LymphClinician share updates on the progress of #CARTCell therapy & bispecific antibodies in #lymphoma: 🎥 https://t.co/YmGsZ2U7eR
#LYMsm #HemOnc
vjhemonc.com
In this discussion, Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, Tycel Phillips, MD, City of Hope, Duarte, CA, and Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, share updates...
0
4
12
Looking forward to it! Excited to discuss outpatient cellular therapy/T cell engage therapy and how to manage the side effects. Leaning on experience from @SarahCannonDocs and @KrishPatelMD as well!
The Advances in Cancer Immunotherapy™: A Focus on Bladder and Genitourinary Cancers program on April 7, features presentations on recent advancements for treating kidney cancer. Learn more and register today: https://t.co/MxQQUKKppI
#LearnACI
@TDorffOnc @TiansterZhang @alantanmd
0
2
5
🚨 New podcast alert! 🎧 Dive into the latest strategies in treating R/R MCL with BTK inhibitors, combo therapies, & overcoming resistance. Featuring experts @KrishPatelMD, @YucaiWangMD, @DrJulieVose, @AdrianMinson, & David Lewis. Listen now! 👇 https://t.co/rupmpNh35g
0
3
0
“Targeted Strategies, Cellular Therapy, and HCT in B-Cell Cancers” with Krish Patel, MD (@KrishPatelMD), and Nirav Shah, MD, MS (@niravshahmd). 3/20 at 7 PM EDT. https://t.co/MGOnshpvZj
#CLL #MCL
0
2
2
#TP53 abnormalities are the main prognostic marker of mantle cell #lymphoma & cannot be replaced by any other MIPI marker. First-line treatment is evolving with BTK inhibitor-based therapies. To assess risk of early relapse, test for TP53 mutations by NGS. https://t.co/JhHNGrost1
0
23
73
🎉 Today we celebrate National Women Physician Day! At @SarahCannonDocs, we're proud of the incredible women leading groundbreaking research & advancing cancer care. Your dedication inspires us every day- thank you! ❤️ 👩⚕️ #WomenInMedicine
#NationalWomenPhysicianDay
#oncology
0
1
3